Corrigendum to Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

Slamon, D.J.; Neven, P.; Chia, S.; Jerusalem, G.; De, Laurentiis M.; Im, S.; Petrakova, K.; Valeria, Bianchi G.; Martin, M.; Nusch, A.; Sonke, G.S.; De, la Cruz-Merino L.; Beck, J.T.; Ji, Y.; Wang, C.; Deore, U.; Chakravartty, A.; Zarate, J.P.; Taran, T.; Fasching, P.A.

doi:10.1016/j.annonc.2021.07.011

서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

S-Space

Publications

Detailed Information

Corrigendum to Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

Cited 0 time in Web of Science Cited 2 time in Scopus

Export

Authors: Slamon, D.J.; Neven, P.; Chia, S.; Jerusalem, G.; De, Laurentiis M.; Im, S.; Petrakova, K.; Valeria, Bianchi G.; Martin, M.; Nusch, A.; Sonke, G.S.; De, la Cruz-Merino L.; Beck, J.T.; Ji, Y.; Wang, C.; Deore, U.; Chakravartty, A.; Zarate, J.P.; Taran, T.; Fasching, P.A.

Issue Date: 2021-10

Publisher: Oxford University Press

Citation: Annals of Oncology, Vol.32 No.10, pp.1307-1307

Abstract: © 2021 The Author(s)The authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected. The authors would like to apologise for any inconvenience caused.